NetraMark Holdings (STU:PF0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PF0 NetraMark Holdings Inc STU:PF0
20 GF Score
Price €0.47
GF Value €0.19
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NetraMark Holdings FFO per Share?

FFO per Share only applies to REITs.

STU:PF0
20GF Score
NetraMark Holdings Inc STU:PF0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NetraMark Holdings (STU:PF0) Overvalued in 2026?

Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued. The current stock price of €0.47 is trading 145.3% above its estimated GF Value™ of €0.19. GuruFocus considers NetraMark Holdings to be Significantly Overvalued.

Key valuation signals for STU:PF0:

  • FFO per Share:
  • GF Value™: €0.19 vs. price of €0.47 (145.3% above fair value)
  • GF Score™: 20/100 with 2 warning signs

No single metric tells the full story. See the STU:PF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NetraMark Holdings Business Description

Other Exchanges AINMF:USAAIAI:Canada
Address 1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
20GF Score

Get the complete analysis for STU:PF0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.47
Price
€0.19
GF Value